Public Health and Economic Benefits of Influenza Vaccination of the Population Aged 50 to 59 Years without Risk Factors for Influenza Complications in Mexico: A Cross-Sectional Epidemiological Study
| Autor: | Roberto Tapia-Conyer, Rodrigo Saucedo-Martínez, Jorge Abelardo Falcón-Lezama, Myrna María Alfaro-Cortes, Miguel Betancourt-Cravioto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Cost effectiveness Vaccination schedule adult-aged population 030106 microbiology Immunology Population lcsh:Medicine burden of disease Article Influenza immunization 03 medical and health sciences 0302 clinical medicine Environmental health Drug Discovery Epidemiology medicine Pharmacology (medical) 030212 general & internal medicine education Mexico Pharmacology education.field_of_study cost effectiveness business.industry Public health lcsh:R vaccination Economic benefits Vaccination middle-income countries Infectious Diseases business influenza |
| Zdroj: | Vaccines Volume 9 Issue 3 Vaccines, Vol 9, Iss 188, p 188 (2021) |
| ISSN: | 2076-393X |
| DOI: | 10.3390/vaccines9030188 |
| Popis: | The Mexican influenza vaccination program does not include a recommendation for people aged 50–59 years without risk factors for influenza complications, and there are limited data regarding the cost-effectiveness of vaccinating this population. To explore the clinical and economic effects of including this population in the vaccination schedule, we performed a cross-sectional epidemiological study using records (2009–2018) from Mexico’s Influenza Surveillance System (SISVEFLU), death records (2010–2015) from the National Mortality Epidemiological and Statistical System, and discharge and hospitalization records (2010–2015) from the Automated Hospital Discharge System databases. A 1-year decision-analytic model was used to assess cost-effectiveness through a decision-tree based on data from SISVEFLU. The primary outcome was influenza cases avoided with associated influenza-related events as secondary outcomes. Including the population aged 50–59 years without risk factors in Mexico’s influenza immunization program would have resulted in 199,500 fewer cases 67,008 fewer outpatient consultations 33,024 fewer emergency room consultations 33,091 fewer hospitalizations 12 fewer deaths. These reductions equate to a substantial public health benefit as well as an economic benefit yielding net savings of 49.8 million US dollars over a typical influenza season. Expansion of the current Mexican vaccination schedule to include these people would be a cost-saving and dominant strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|